Project Grant R21CA274500
Award Date
9/20/23
Completion Date
8/31/25
Dollars Obligated
$387K
Federal Agency
National Cancer Institute
Federal Grant Program
93.393
Assistance Type
Project Grant
Place of Performance
Michigan, USA
Similar Awards
This Project Grant award from the National Cancer Institute (CFDA 93.396, Cancer Biology Research) aims to investigate key transcriptional regulators that drive prostate cancer lineage plasticity, which can lead to more lethal cancer subtypes. The $509,246 award to the Regents of the University of Michigan will fund a 5-year research project to: 1) determine how these transcriptional regulators modulate prostate cancer cell differentiation and hallmarks, 2) understand how the regulators are...
This federal Project Grant award for $538,553, provided by the National Cancer Institute (CFDA 93.394 - Cancer Detection and Diagnosis Research), will support research to define the role of quantitative multiparametric MRI (mpMRI) features and circulating tumor cells (CTCs) as early markers of patient outcomes after radiation therapy (RT) and androgen deprivation therapy (ADT) in prostate cancer patients. The 5-year project, which commenced on April 1, 2025, will be conducted by the University...
The National Cancer Institute awarded a Project Grant (CFDA 93.394 - Cancer Detection and Diagnosis Research) totaling $568,151 to the Regents of the University of Michigan. The grant will fund research to develop a real-time functional photoacoustic imaging platform with the capability to quantitatively evaluate prostate cancer tumor heterogeneity and microenvironment for improved prostate cancer diagnosis and prognosis. The research aims to optimize photoacoustic-nanoparticle contrast...
This federal Project Grant award of $644,622 from the National Cancer Institute (NCI) under the Cancer Treatment Research program (CFDA 93.395) aims to enhance radioligand therapy for prostate cancer through the development of biomarker and dosimetry-guided personalized treatment approaches. The key objectives are to: 1) develop a novel method for bone marrow dosimetry using macro/micro Monte Carlo modeling, 2) build predictive models to estimate absorbed radiation doses from pre-therapy PET...
This Project Grant award from the National Cancer Institute (CFDA 93.395 - Cancer Treatment Research) provides $571,271 to the University of Texas Health Science Center at Houston to develop a targeted therapy for the treatment of metastatic castration-resistant prostate cancer (MCRPC). The research aims to synthesize a prostate-specific membrane antigen (PSMA)-targeted drug conjugate that can selectively deliver the microtubule inhibitor cryptophycin to MCRPC tumors. The project will...
This Project Grant award from the National Cancer Institute (CFDA 93.393 - Cancer Cause and Prevention Research) will support research at Weill Medical College of Cornell University to investigate the role of the androgen receptor (AR) in both normal prostate cell function and prostate cancer development. The $564,543 award, effective March 1, 2025 through February 28, 2030, will enable the research team to determine the factors that mediate the switch between AR's normal, growth-suppressive...
This federal Project Grant award from the National Cancer Institute (NCI) under the Cancer Cause and Prevention Research program (CFDA 93.393) provides $327,496 to the University of Missouri System to design and develop implementation interventions aimed at improving the quality of active surveillance for men with favorable-risk prostate cancer. The project, awarded on September 13, 2024, seeks to: 1) assess key implementation determinants, 2) design and tailor interventions to support quality...
The National Cancer Institute (NCI) awarded a $713,700 Project Grant under the Cancer Cause and Prevention Research program (CFDA 93.393) to the Regents of the University of Michigan. The 5-year grant, beginning on Sep 5, 2024, will fund the development and testing of a multi-component, multi-level intervention to reduce overuse of total thyroidectomy for patients with low-risk thyroid cancer. The intervention aims to promote "less extensive surgery by surgeons" (LESS) by targeting...
The National Cancer Institute (NCI) awarded a $535,334 Project Grant (CFDA 93.396 - Cancer Biology Research) to the Albert Einstein College of Medicine to conduct research on the non-autonomous role of androgen signaling in prostate tumorigenesis. The project aims to investigate how androgen receptor (AR) activation in prostatic stromal cells, specifically those expressing the GLI1 transcription factor, can promote prostate epithelial oncogenesis and tumor development through paracrine signaling...
The National Cancer Institute (NCI) awarded a $185,760 Project Grant under the Cancer Research Manpower (CFDA 93.398) program to The Regents of the University of California, San Francisco (UCSF) to develop a novel tumor-targeted combination therapy for metastatic castration-resistant prostate cancer (mCRPC). The project aims to enhance efficacy and reduce toxicity by co-delivering cytotoxic drugs and the radioactive isotope Actinium-225 directly to cancer cells. Key objectives include developing...